PARs European Patent Granted for Bone Marrow Edema Lesions

ASX RELEASE 16 January 2018 European Patent Granted for Bone Marrow Edema Lesions Highlights: • European patent granted for treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS). • Paradigm has initiated the process of validating the patent in all key European member states. • The European registration solidifies global patent protection. • Paradigm has additional intellectual property rights via its exclusive Supply Agreement with bene pharmaChem to injectable PPS for its orthopaedic indications. Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce that it has been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS). The patent (no 2670412 ), entitled: ‘Treatment of bone marrow edema (oedema) with polysaccharides’ was granted on the 3rd January 2018. Paradigm has initiated the process of validating the patent in the following European member states: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, Great Britain, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Sweden, and Turkey. The Company anticipates that the patent will be validated in these individual member states over the coming six months, providing an effective patent life of 20 years. The patent expires on 2nd February 2032. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in United States, Japan, China, Canada, Taiwan, Singapore and Australia. Paradigm has an additional level of market exclusivity via its Supply Agreement with bene pharmaChem. Bene pharmaChem is the original manufacturer of PPS and its manufacturing process is protected via Trade Secrets. The Supply Agreement with bene pharmaChem provides Paradigm with exclusive rights to the injectable PPS (for use in humans) for all its orthopaedic indications for a term of 20 years (with the right to extend the term). Paradigm’s CEO, Paul Rennie, said the granting of the Eu ropean Patent now means Paradigm has Intellectual Property Rights in the major pharmaceutical markets of the USA, Japan and Europe. In addition to the patent Paradigm has exclusive rights to the bene pharmaChem injectable PPS for its orthopaedic indications in humans. During this calendar year, Paradigm will release the results of its two phase 2 arthritis clinical trials. Granted patents in Europe, USA and Japan along with data from two randomised double-blind placebo-controlled phase 2 clinical trials provides a solid foundation for our future plans including our partnering discussions. FOR FURTHER INFORMATION PLEASE CONTACT: Paul Rennie Director & CEO Paradigm Biopharmaceuticals Ltd Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA ABN: 94 169 346 963 Web: http://paradigmbiopharma.com/ Email: [email protected] Mobile International: +61 437 778 300 Mobile (Australia): 0437 778 300

The release as fetched from its publisher. paradigmbiopharma.com ↗